Cargando…
Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial
BACKGROUND: Severe posttraumatic stress disorder (PTSD) is a prevalent and debilitating condition in the United States. and globally. Using pooled efficacy data from six phase 2 trials, therapy using 3,4-methylenedioxymethamphetamine (MDMA) appeared cost-saving from a payer’s perspective. This study...
Autores principales: | Marseille, Elliot, Mitchell, Jennifer M., Kahn, James G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880875/ https://www.ncbi.nlm.nih.gov/pubmed/35213554 http://dx.doi.org/10.1371/journal.pone.0263252 |
Ejemplares similares
-
Correction: Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial
por: Marseille, Elliot, et al.
Publicado: (2022) -
The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD
por: Marseille, Elliot, et al.
Publicado: (2020) -
The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study
por: Avanceña, Anton L. V., et al.
Publicado: (2022) -
Posttraumatic Growth After MDMA‐Assisted Psychotherapy for Posttraumatic Stress Disorder
por: Gorman, Ingmar, et al.
Publicado: (2020) -
Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder
por: Thal, Sascha B., et al.
Publicado: (2018)